854 reports of this reaction
3.2% of all BREXPIPRAZOLE reports
#5 most reported adverse reaction
AKATHISIA is the #5 most commonly reported adverse reaction for BREXPIPRAZOLE, manufactured by Otsuka America Pharmaceutical, Inc.. There are 854 FDA adverse event reports linking BREXPIPRAZOLE to AKATHISIA. This represents approximately 3.2% of all 26,345 adverse event reports for this drug.
Patients taking BREXPIPRAZOLE who experience akathisia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
AKATHISIA is moderately reported among BREXPIPRAZOLE users, representing a notable but not dominant share of adverse events.
In addition to akathisia, the following adverse reactions have been reported for BREXPIPRAZOLE:
The following drugs have also been linked to akathisia in FDA adverse event reports:
AKATHISIA has been reported as an adverse event in 854 FDA reports for BREXPIPRAZOLE. This does not prove causation, but indicates an association observed in post-market surveillance data.
AKATHISIA accounts for approximately 3.2% of all adverse event reports for BREXPIPRAZOLE, making it a notable side effect.
If you experience akathisia while taking BREXPIPRAZOLE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.